- Home
- MKLY vs SGMT Comparison
MKLY vs SGMT Comparison
Compare MKLY & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MKLY | SGMT |
|---|---|---|
| Founded | 2025 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.6M | 238.7M |
| IPO Year | 2025 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MKLY | SGMT |
|---|---|---|
| Price | $10.01 | $6.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.71 |
| AVG Volume (30 Days) | 77.1K | ★ 554.6K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $1.73 |
| 52 Week High | $10.05 | $11.41 |
Technical Indicators
Market Signals| Indicator | MKLY | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 49.46 |
| Support Level | N/A | $5.43 |
| Resistance Level | N/A | $6.42 |
| Average True Range (ATR) | 0.00 | 0.28 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 0.00 | 61.25 |
Price Performance
Historical ComparisonAbout MKLY McKinley Acquisition Corporation Class A Ordinary Shares
McKinley Acquisition Corp is a blank check company.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.